drugset / Trial / NCT00628914

Brain Mechanisms and Targeting Insomnia in Major Depression

NCT00628914

Phase 4 Unknown 60 enrolled University of California, Los Angeles
RandomizedParallel-groupDouble-blindTreatment

Summary

Preliminary studies suggest that the response to antidepressant medication can be accelerated by targeting insomnia with adjunctive use of eszopiclone. It is not yet known what mechanism(s) support this acceleration in response, though preliminary findings support the hypothesis that early restoration of sleep may facilitate BDNF-based effects of antidepressant medications. The optimal duration of co-treatment is also unknown. This study will test specific hypotheses about brain mechanisms and evaluate the effects of continued eszopiclone beyond the time window when response acceleration should be observed.

Timeline

Start
2008-05
Primary completion
2009-11
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg
Background Escitalopram Small molecule 10 mg